Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas

Bone Marrow Transplantation volume 47, pages 940–945 (2012)Cite this article

Abstract

Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas that are considered incurable. The role of allogeneic hematopoietic SCT (HSCT) in the treatment of CTCL is not well defined but may provide potent graft-vs-lymphoma (GVL) activity independent of the conditioning therapy. We present outcomes of 12 extensively-pretreated patients with CTCL who underwent allogeneic HSCT using, most commonly, a reduced intensity conditioning regimen. Median age at diagnosis of CTCL was 49 years, and median time to transplantation from diagnosis was 3.3 years. Transplantation induced and maintained CR in six patients with active disease, supporting the presence of a GVL effect. TRM was low, and 42% of patients were alive and disease-free a median duration of 22 months after transplant. Two patients showed strong and direct evidence of a GVL-effect with a direct response to withdrawal of immunosuppression or to donor leukocyte infusion. Our data show that HSCT can provide long-term disease control in patients with advanced CTCL, which otherwise was refractory to immunotherapy and chemotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. van Doorn R, Van Haselen CW, van Voorst Vader PC, Geerts M-L, Heule F, de Rie M et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000; 136: 504–510.

    Article  CAS  PubMed  Google Scholar 

  2. Bernengo MG, Quaglino P, Novelli M, Cappello N, Doveil GC, Lisa F et al. Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, haematological and immunological features. Ann Oncol 1998; 9: 857–863.

    Article  CAS  PubMed  Google Scholar 

  3. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Zain J, O’Connor OA . Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest New Drugs 2010; 28: S58–S78.

    Article  PubMed  Google Scholar 

  5. Erter J, Alinari L, Darabi K, Gurcan M, Garzon R, Marcucci G et al. New targets of therapy in T-cell lymphomas. Curr Drug Targets 2010; 11: 482–493.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther 2010; 10: 997–1008.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 4485–4491.

    Article  CAS  PubMed  Google Scholar 

  8. Rook AH, Kuzel TM, Olsen EA . Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am 2003; 17: 1435–1448.

    Article  PubMed  Google Scholar 

  9. Choi J, Foss F . Cutaneous T-cell lymphoma: biologic targets for therapy. Curr Hematol Malig Rep 2007; 2: 272–277.

    Article  PubMed  Google Scholar 

  10. Horwitz SM . Novel therapies for cutaneous T-cell lymphomas. Clin Lymphoma Myeloma 2008; 8: S187–S192.

    Article  CAS  PubMed  Google Scholar 

  11. Bigler RD, Crilley P, Micaily B, Brady LW, Topolsky D, Bulova S, et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 1991; 7: 133–137.

    CAS  PubMed  Google Scholar 

  12. Goldstein SC, Porter DL . Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. Expert Rev Hematol 2010; 3: 301–314.

    Article  CAS  PubMed  Google Scholar 

  13. Molina A, Zain J, Arber DA, Angelopolou M, O'Donnell M, Murata-Collins J et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 2005; 23: 6163–6171.

    Article  PubMed  Google Scholar 

  14. Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol 2010; 28: 2365–2372.

    Article  PubMed  Google Scholar 

  15. Delioukina M, Zain J, Palmer JM, Tsai N, Thomas S, Forman S . Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant 2012; 47: 65–72.

    Article  CAS  PubMed  Google Scholar 

  16. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Amer Statist Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  17. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713–1722.

    Article  CAS  PubMed  Google Scholar 

  18. Lansigan F, Foss FM . Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010; 70: 273–286.

    Article  CAS  PubMed  Google Scholar 

  19. Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ . Update on treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 2009; 21: 131–137.

    Article  CAS  PubMed  Google Scholar 

  20. Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 1870–1877.

    Article  CAS  PubMed  Google Scholar 

  21. Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 4492–4499.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grants from The Leukemia & Lymphoma Society (7000-02) and NIH (K24 CA11787901) (DLP).

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA, USA

    V R Paralkar, S D Nasta, J Smith, P Vassilev, S C Goldstein, A Loren & D L Porter

  2. Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA

    K Morrissey, A H Rook & E J Kim

  3. Division of Bone Marrow Transplantation, Temple University School of Medicine, Philadelphia, PA, USA

    M E Martin

Authors
  1. V R Paralkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S D Nasta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Morrissey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Vassilev
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M E Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S C Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Loren
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A H Rook
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D L Porter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V R Paralkar.

Ethics declarations

Competing interests

Alain H Rook is on the Speaker's bureau of Therakos, and is a consultant for HY Biopharma. Ellen J Kim has obtained research funding from TenX, Biocryst, Genmab, Glouchester, Celgene, and is a consultant for Eisai. Other authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paralkar, V., Nasta, S., Morrissey, K. et al. Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas. Bone Marrow Transplant 47, 940–945 (2012). https://doi.org/10.1038/bmt.2011.201

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.201

Keywords

This article is cited by

Search

Advanced search

Quick links